
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Thyroid problems can be worrisome, but relatively few children referred for workup for an abnormal thyroid test have clinically significant disease. Choosing the right screening tests can prevent these costly encounters without compromising children whose test results warrant close follow-up and possible intervention.






